Outcomes of gastric and small Intestinal GISTs (Gastrointestinal Stromal Tumors) after curative resection and aggressive re-resection of recurrence; in Imatinib era: A propensity matched analysis.

Abstract

Background: Surgical resection remains the mainstay of treatment for localized GISTs. Prognostication and need for adjuvant imatinib are based on risk stratification which includes tumor site as an important factor with small intestine lesions having poor prognosis as compared to gastric primary. Aim of this study is to evaluate oncological outcomes of gastric and small intestinal GIST patients undergoing curative resection, focusing on the role of primary tumor site as a prognostic indicator.